PURPOSE: Owing to the advent of refined chest computed tomography and mass screening program for lung cancer introduced to Japan since 1987, smaller lung cancers have been discovered, and the early staged disease as candidates for surgical resection is increasing. In this study, we retrospectively reviewed the lung cancer (LC) patients who underwent surgical resection in our institution, and investigated the contribution of surgical results to the outcome in all LC patients treated in our institution.
METHODS: From 1980 to 2009, total 3541 LC patients underwent complete resection in the Niigata Cancer Center Hospital. The surgical results were analyzed in each decade (1980's: n = 629; 1990's: n = 1233; 2000's: n = 1679). The outcome of all treated LC patients was analyzed in every 5-year (1980: n = 80; 1985: n = 149; 1990: n = 219; 1995: n = 283; 2000: n = 317; 2005: n = 395).
RESULTS: In each decade, the overall 5-year survival rate of the patients who underwent complete resection was 57.9%, 62.9%, 73.6%, respectively. The surgical results has been improved accompanied by the increased proportion of pathological stage I disease from 60% in the 1980’s, to 67% in the 1990’s, to 76% in the 2000’s. The outcome of all treated LC patients has also been improved, and the 5-year survival rate was 26.3%, 25.5%, 34.7%, 36.0%, 39.4%, 40.0% in each year, respectively. From 1980 to 2005, the 5-year survival rate of all treated LC patients was improved 13.7%, and surgical results contributed to 9 of the 13.7% improvement.
CONCLUSIONS: Both surgical results for LC patients and the outcome of all treated LC patients were improved in recent 30 years. Increased small and early staged disease, and consequent improved surgical results contributed to the outcome improvement in all treated LC patients.
CLINICAL IMPLICATIONS: The mass screening program for lung cancer may contribute to outcome improvement in LC patients by detecting the small and early staged disease as candidates for surgical resection.
DISCLOSURE: The following authors have nothing to disclose: Terumoto Koike, Teruaki Koike, Yasushi Yamato, Katsuo Yoshiya, Akira Yokoyama, Tatsuya Takenouchi
No Product/Research Disclosure Information